Sustained-Release Isosorbide-5-Mononitrate Improves Exercise Capacity 30 Minutes after Oral Application

Guzik, Justyna; Kanopka, M.; Maciejewicz, Janusz; Maziarz, Andrzej; Stepien, Jacqueline M

doi:10.2165/00044011-199714020-00005

Cited by 4 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The early onset of effect of IS-5-MN after administration of the sustained-release formulation confirmed the results of a recently published observation in patients with stable angina of effort. 15 The authors investigated the time to moderate angina PHARMACOKINETICS AND PHARMACODYNAMICS pectoris during treadmill exercise after administering the same pharmaceutical formulation as used in the present study. The patients exercised before and 30 minutes after drug administration but with treadmill exercise performed on different days.…”

Section: Discussionmentioning

confidence: 99%

“…Following administration of placebo, only minor physiological variations of the a/b-ratio of the finger pulse curve were observed up to 4 hours after administration (Figure 1). The increase in the a/b-ratio recorded 6 hours after administration seemed most likely related to the intake of lunch served 15 blood pressure following orthostatic challenge were observed after placebo (Figure 2), while there was a continuously increasing heart rate within the period of investigation (6 hours) under the latter condition (Figure 3).…”

Section: Hemodynamic Effectsmentioning

confidence: 96%

See 1 more Smart Citation

Comparison of the Initial Hemodynamic Effects of Immediate‐Release versus Sustained‐Release Isosorbide‐5‐Mononitrate following Single Oral Doses

Trenk

Hinder

Stengele

et al. 2000

The Journal of Clinical Pharma

View full text Add to dashboard Cite

In this double-blind, randomized, placebo-controlled cross-over study, the authors investigated the initial time course of effects of isosorbide-5-mononitrate (IS-5-MN) on hemodynamic parameters in 15 healthy male volunteers after administering a single oral dose of either an immediate-release formulation (IS-5-MN 20 mg) or of a sustained-release formulation (IS-5-MN 50 mg). The latter formulation released 15 mg IS-5-MN immediately, while 35 mg of the dose was sustained release. The onset of effect on the a/b-ratio of the finger pulse curve (20 minutes after administration) and on heart rate following orthostatic challenge (30 minutes) was not different following ingestion of either the immediate-release or the sustained-release formulation. Only the systolic blood pressure following orthostatic challenge was affected earlier after ingestion of the immediate-release form of IS-5-MN (10 vs. 30 minutes). There was no statistically significant difference in the maximum effect on the measured hemodynamic parameters between the two formulations. There was no significant difference with respect to the effect per dose between both of the active treatments (i.e., IS-5-MN 20 mg immediate release and IS-5-MN 50 mg sustained release) within 6 hours after administration. The hemodynamic findings were consistent with the observed rates of the increase of plasma concentrations of IS-5-MN following both formulations. Thus, the administration of the sustained-release formulation of IS-5-MN 50 mg caused similar maximum effects when compared with an immediate-release formulation (20 mg). While the onset of effect of IS-5-MN on the a/b-ratio of the finger pulse curve and on heart rate following orthostasis was similar after administration of either the immediate- or the sustained-release formulation, the onset of effect of the sustained-release formulation on systolic blood pressure orthostasis was determined slightly later. However, the latter difference seems to be of minor clinical relevance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Hemodynamic Effectsmentioning

confidence: 96%

Comparison of the Initial Hemodynamic Effects of Immediate‐Release versus Sustained‐Release Isosorbide‐5‐Mononitrate following Single Oral Doses

Trenk

Hinder

Stengele

et al. 2000

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Time to onset (P1) and to moderate (P2) angina 30 minutes after administration of ISMN or placebo when compared with baseline 16 …”

Section: Nitrate Tolerancementioning

confidence: 99%

“…The short‐term antianginal efficacy of this combined immediate‐release and sustained‐release preparation was investigated in two studies. Guzik et al 16 set out to measure whether clinical efficacy could be observed 30 minutes after taking an ISMN‐SR 50 mg capsule. Seventeen men and three women aged between 36 and 67 entered a randomised, double‐blind, placebo‐controlled crossover study.…”

Section: Efficacy Datamentioning

confidence: 99%

A Sustained Release Formulation of Isosorbide‐5‐mononitrate With a Rapid Onset of Action

Arthur

Mehmel

1999

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYThe clinical efficacy of a combined immediate‐release and sustained‐release preparation of isosorbide‐5‐mononitrate for angina pectoris is observed within a few minutes of administration. The preparation reduces the number of silent and painful ischaemic episodes and increases work and exercise capacity. The pharmacokinetic profiles accord with the circadian variation in cardiovascular disease. Drug levels fall significantly at night and tolerance to the haemodynamic and antianginal effects is not seen. Once‐daily administration is appreciated by patients. The preparation also shows promise in treating heart failure.

show abstract

Optimal Nitrate Therapy with a Once-daily Sustained-release Formulation of Isosorbide Mononitrate

Waller¹

1999

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Sustained-Release Isosorbide-5-Mononitrate Improves Exercise Capacity 30 Minutes after Oral Application

Cited by 4 publications

References 12 publications

Comparison of the Initial Hemodynamic Effects of Immediate‐Release versus Sustained‐Release Isosorbide‐5‐Mononitrate following Single Oral Doses

Comparison of the Initial Hemodynamic Effects of Immediate‐Release versus Sustained‐Release Isosorbide‐5‐Mononitrate following Single Oral Doses

A Sustained Release Formulation of Isosorbide‐5‐mononitrate With a Rapid Onset of Action

Optimal Nitrate Therapy with a Once-daily Sustained-release Formulation of Isosorbide Mononitrate

Contact Info

Product

Resources

About